Company Announcements - 2016
-
Appendix 3Y x522 December 2016
Change of Director's Interest Notice for Dr Michael Monsour, Dr Thomas Lonngren, Mr Ross Mangelsdorf, Mr Warren Brooks, and Mr Carl Stubbings.
-
Appendix 3B22 December 2016
New issue announcement, application for quotation of additional securities and agreement.
-
R&D Tax Receipt22 December 2016
Analytica announces the receipt of $1,157k from the Australian Taxation Office under the Research and Development incentive related to the financial year to 30th June 2016.
-
Annual General Meeting24 November 2016
-
Appendix 4C28 October 2016
Analytica presents its quarterly cash flow for the period ending 30 Sept 2016.
-
Notice of Meeting and Proxy Form24 October 2016
Analytica advises that the 2016 Annual General Meeting will be held in the Flinders Room, Level 1, Christie Conference Centre, 320 Adelaide St Brisbane at 10:00am Thursday 24th November 2016. Also included with this notice are a voting proxy form with instructions, and a summary Annual Report.
-
Chelsea Cornelius Receives MTAA Outstanding Achievement Award24 October 2016
Analytica Ltd is pleased to announce that Ms Chelsea Cornelius, Analytica’s Product Development Manager, has recently been presented with the Medical Technology Association of Australia (MTAA) Outstanding Achievement Award. This award recognises an individual who has contributed in a significant and outstanding way to the development of medical technology that improves patient outcomes and excellence.
-
Placement to Inov8 LLC5 October 2016
Analytica announces the allotment of 35,714,286 shares ($250,000) to cornerstone investor INOV8 LLC. The shares were issued at $0.007.
-
Analytica Corporate Governance Statement and Appendix 4G30 September 2016
-
Annual Report 201630 September 2016
Analytica presents its Consolidated Financial Statements for the year ended 30 June 2016.
-
PeriCoach Clinical Publication on Patient with Multiple Sclerosis and Faecal Incontinence15 September 2016
Analytica continues to execute their strategy for demonstrating PeriCoach® clinical efficacy with the company’s latest publication in the internationally regarded Journal of Urology and Research. The case study details the experience of a 70-year-old female with Multiple Sclerosis (MS) and faecal incontinence using PeriCoach as an adjunct treatment to her physical therapy sessions.
-
Placement to Inov8 LLC1 September 2016
Analytica announces the allotment of 35,714,285 shares ($250,000) to cornerstone investor INOV8 LLC today. The shares were issued at $0.007.
-
Appendix 3Y x21 September 2016
Appendix 3Y's for 2 directors showing the inclusion of options that were granted by Shareholders at the Annual General Meeting held on the 241h November 2015.
-
Full Year Results31 August 2016
Analytica presents its Appendix 4E and Financial Statements for the year ended 30 June 2016.
-
PeriCoach granted patent protection in China3 August 2016
Analytica has been granted patent protection in the People’s Republic of China for the device’s unique pelvic floor force sensing technology.
-
PeriCoach sexual health indication clarification from USFDA29 July 2016
Analytica has received clarification from the US Food and Drug Administration regarding additional marketing claims for improved sexual function in women from strengthening their pelvic floors using the PeriCoach system.
-
Appendix 4C28 July 2016
Analytica presents its quarterly cash flow for the period ending 30 June 2016.
-
Share placement of $500k to cornerstone investor27 July 2016
Analytica is pleased to announce the further placement of new fully paid ordinary shares to our American Virgin Islands cornerstone investor INOV8 LLC.
-
AutoStart Burette granted US Patent15 July 2016
Analytica is pleased to announce that the AutoStart burette system has been granted patent protection by the US Patent and Trademarks Office. US Patent 9352080 has a priority date of 13 October 2005 and will expire on 17 Jan 2031.
-
Analytica receives FDA Over-the-Counter clearance for PeriCoach12 July 2016
Analytica Ltd is pleased to announce that the US Food and Drug Administration has granted the company over-the-counter clearance for the PeriCoach system, previously available in the US by prescription only.
-
AutoStart Burette listed through QLD Health Tender3 June 2016
Analytica is pleased to announce that the AutoStart® infusion system product has been listed on the Queensland Health purchasing schedule.
-
PeriCoach Case Studies published in Peer Reviewed Urology Journal19 May 2016
Analytica is pleased to announce the publication of case studies in the Urologic Nursing Journal of the US Society of Urologic Nurses and Associates
-
Notice of Initial Substantial Holder2 May 2016
New substantial holder - Inov8 LLC
-
Appendix 4C29 April 2016
Analytica presents its Appendix 4C for the quarter ended 31 March 2016.
-
Share Issue Compliance Documents28 April 2016
-
Appendix 3Y27 April 2016
Change of Director's Interest - 2 Notices.
-
Results of EGM22 April 2016
Analytica advises that all resolutions were passed.
-
Share Purchase Plan Results20 April 2016
Analytica is pleased to announce that the Share Purchase Plan was well supported by shareholders with $567,700 being received.
-
Investor Update Webcast Recording7 April 2016
Analytica is pleased to present a recording of the webcast held this morning hosted by Analytica CEO, Geoff Daly.
-
Investor Update Webcast5 April 2016
Analytica invites investors to a webcast hosted by Geoff Daly, CEO on Thursday 7 April 2016 at 9am (Brisbane time).
-
Extraordinary General Meeting23 March 2016
The EGM will be held Friday, 22 April 2016 at 10.30am (Brisbane time), at the Oxley Room, Level 1, Christie Corporate, 320 Adelaide Street, Brisbane.
-
Section 708A Notice and Appendix 3B22 March 2016
-
Capital Raising18 March 2016
Analytica is pleased to announce the following capital raising initiatives.
-
Analytica implements expenditure reduction initiatives10 March 2016
Analytica has announced a number of initiatives to reduce expenditure.
-
Appendix 3Y1 March 2016
Change of Director's Interest - 4 Notices.
-
Appendix 3B - Exercise and lapse of listed options - ALTO1 March 2016
Analytica advises that 418,602 options (ASX:ALTO) exercisable at $0.011 were exercised and 118,953,591 options were not exercised by the expiry date of 29 February 2016.
-
Appendix 4D and Half Year Reports29 February 2016
Half Year Report for the 6 months ended December 2015.
-
Notification of Expiry of Listed Options05 February 2016
Analytica advises that the attached letter has been sent to holders of Analytica listed options, as notification of the expiry of their options on 29th February 2016.
-
Appendix 4C29 January 2016
Analytica presents its Appendix 4C for the quarter ended 31 December 2015.
-
Appointment of additional PeriCoach distributors for UK and Ireland29 January 2016
Analytica announces the appointment of two new distribution partners for UK and Ireland.
-
R and D Tax Incentive Receipt18 January 2016
Analytica is pleased to announce the receipt of $1,901k from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2015.
-
Change of Registered Office Address15 January 2016
Analytica advises that effective from the 15th January 2016 that it has changed its registered office to Analytica Ltd, c/- Avance Chartered Accountants, 222 Bazaar Street Maryborough, Queensland 4650.